News & Updates

Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis

24 Apr 2024

In the treatment of radiographic axial spondyloarthritis (r-axSpA), the 2-year incidence of spinal radiographic progression is low and not different between secukinumab and adalimumab biosimilar, as shown in the phase IIIb study SURPASS study.

Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis

24 Apr 2024

Investigational agent works well for migraine in pooled analysis

24 Apr 2024 by

Treatment with the investigational agent AXS-07 significantly alleviates pain and most bothersome symptoms (MBS) in patients with migraine, according to results of a pooled analysis of the phase III MOMENTUM and INTERCEPT trials presented at AAN 2024.

Investigational agent works well for migraine in pooled analysis

24 Apr 2024

SGLT2 inhibitors a promising gout medication in T2D

23 Apr 2024 by

The use of sodium-glucose cotransporter type 2 (SGLT2) inhibitors lowers the risk of incident gout or recurrent gout flares among patients with type 2 diabetes who are taking metformin, as shown in a study.

SGLT2 inhibitors a promising gout medication in T2D

23 Apr 2024

Erenumab helps with rosacea-associated flushing, erythema

23 Apr 2024

Monthly subcutaneous injections of the anti–CGRP-receptor monoclonal antibody erenumab appear to be beneficial in the management of flushing and chronic redness among individuals with rosacea, according to a study.

Erenumab helps with rosacea-associated flushing, erythema

23 Apr 2024

Supplementation with essential amino acid improves liver health in teen girls with PCOS

23 Apr 2024 by

Short-term supplementation with a selective essential amino acid (EAA)-containing product significantly improved liver-related outcomes among adolescent girls with polycystic ovarian syndrome (PCOS) in a recent study.

Supplementation with essential amino acid improves liver health in teen girls with PCOS

23 Apr 2024

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

21 Apr 2024

Tirbanibulin 1% ointment proves safe and effective in patients with multiple actinic keratoses (AKs) treated in real-world settings, as shown in a study.

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

21 Apr 2024

Do GLP1 receptor agonists increase thyroid cancer risk?

20 Apr 2024 by

Use of glucagon-like peptide 1 (GLP1) receptor agonists does not contribute to an elevated risk of thyroid cancer, as shown in a Scandinavian cohort study with a mean follow-up of nearly 4 years.

Do GLP1 receptor agonists increase thyroid cancer risk?

20 Apr 2024

LDL-C lowering with bempedoic acid reduces cardiovascular events in high-risk population

19 Apr 2024

The use of bempedoic acid helps lower low-density lipoprotein cholesterol (LDL-C) levels and subsequently reduce cardiovascular events in individuals at high cardiovascular risk, according to the CLEAR* Outcomes trial.

LDL-C lowering with bempedoic acid reduces cardiovascular events in high-risk population

19 Apr 2024

Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia

19 Apr 2024 by

Monthly administration of olezarsen 50 or 80 mg significantly reduced triglyceride levels in patients with predominantly moderate hypertriglyceridemia (HTG) and elevated cardiovascular (CV) risk, according to the Bridge-TIMI 73a trial presented at ACC.24.

Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia

19 Apr 2024

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?

18 Apr 2024

Patients using multiple insulin injections demonstrate no significant difference in changes to A1c, insulin requirements, or weight after a year of treatment with a sodium glucose transporter 2 (SGLT2) inhibitor or glucagon-like peptide 1 (GLP1) receptor agonist, as shown in a study.

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?

18 Apr 2024

News & Updates

Filter by Specialty:

Specialty:

Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis

Secukinumab, adalimumab biosimilar compare favourably for treating axial spondyloarthritis

Investigational agent works well for migraine in pooled analysis

Investigational agent works well for migraine in pooled analysis

SGLT2 inhibitors a promising gout medication in T2D

SGLT2 inhibitors a promising gout medication in T2D

Erenumab helps with rosacea-associated flushing, erythema

Erenumab helps with rosacea-associated flushing, erythema

Supplementation with essential amino acid improves liver health in teen girls with PCOS

Supplementation with essential amino acid improves liver health in teen girls with PCOS

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

Tirbanibulin 1% ointment for actinic keratoses passes muster in real world

Do GLP1 receptor agonists increase thyroid cancer risk?

Do GLP1 receptor agonists increase thyroid cancer risk?

LDL-C lowering with bempedoic acid reduces cardiovascular events in high-risk population

LDL-C lowering with bempedoic acid reduces cardiovascular events in high-risk population

Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia

Olezarsen reduces triglyceride levels in adults with hypertriglyceridemia

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?

Is it safe to use GLP1 agonists, SGLT2 inhibitors in patients on multiple insulin injections?